{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:17:23Z","timestamp":1781921843265,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,12,3]],"date-time":"2013-12-03T00:00:00Z","timestamp":1386028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s40265-013-0156-6","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T09:57:09Z","timestamp":1385978229000},"page":"127-133","source":"Crossref","is-referenced-by-count":41,"title":["Macitentan: First Global Approval"],"prefix":"10.1007","volume":"74","author":[{"given":"Trina","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"McKeage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,3]]},"reference":[{"issue":"129","key":"156_CR1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09059180.00001713","volume":"22","author":"A Seferian","year":"2013","unstructured":"Seferian A, Simonneau G. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow? Eur Respir Rev. 2013;22(129):217\u201326.","journal-title":"Eur Respir Rev"},{"issue":"126","key":"156_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1183\/09059180.00004812","volume":"21","author":"O Sitbon","year":"2012","unstructured":"Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev. 2012;21(126):321\u20137.","journal-title":"Eur Respir Rev"},{"issue":"17","key":"156_CR3","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1021\/jm3009103","volume":"55","author":"MH Bolli","year":"2012","unstructured":"Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N\u2032-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55(17):7849\u201361.","journal-title":"J Med Chem"},{"key":"156_CR4","unstructured":"US FDA. FDA approves Opsumit to treat pulmonary arterial hypertension [media release]. http:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm371362.htm . Accessed 18 Oct 2013."},{"key":"156_CR5","unstructured":"Actellion Pharmaceutials Ltd. Actelion receives Health Canada approval of Opsumit (macitentan) for the long-term treatment of pulmonary arterial hypertension [media release]. http:\/\/www.actelion.com . Accessed 12 Nov 2013."},{"key":"156_CR6","unstructured":"Actelion Pharmaceuticals US Inc. Full prescribing information: Opsumit\u00ae (macitentan) tablets. 2013. http:\/\/opsumit.com\/splash\/pdf\/OPSUMIT-Full-Prescribing-Information.pdf . Accessed 30 Oct 2013."},{"key":"156_CR7","unstructured":"European Medicines Agency. Summary of opinion: Opsumit (macitentan). 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002697\/WC500153142.pdf . Accessed 30 Oct 2013."},{"issue":"9","key":"156_CR8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318.","journal-title":"N Engl J Med"},{"key":"156_CR9","unstructured":"Actelion Pharmaceuticals Ltd. Actelion receives US FDA approval of Opsumit (macitentan) for the treatment of pulmonary arterial hypertension [media release]. http:\/\/www.actelion.com\/en\/journalists\/news-archive.page?newsId=1736781 . Accessed 18 Oct 2013."},{"key":"156_CR10","unstructured":"Actelion. MAESTRO (macitentan in Eisenmenger syndrome to restore exercise capacity) [ClinicalTrials.gov identifier NCT01743001] US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01743001?term=macitentan+Eisenmenger&rank=1 . Accessed 31 Oct 2013."},{"key":"156_CR11","unstructured":"Actelion. Macitentan for the treatment of digital ulcers in systemic sclerosis patients (DUAL-1) [ClinicalTrials.gov identifier NCT01474109] US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01474109?term=macitentan+ischaemic+digital+ulcers&rank=1 . Accessed 31 Oct 2013."},{"key":"156_CR12","unstructured":"Actelion. Macitentan in combo with dose-dense temozolomide in patients with recurrent glioblastoma [ClinicalTrials.gov identifier NCT01499251] US National Institutes of Health, ClinicalTrials.gov. 2013. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01499251?term=macitentan+glioblastoma&rank=1 . Accessed 31 Oct 2013."},{"key":"156_CR13","doi-asserted-by":"crossref","unstructured":"Raghu G, Million-Rosseau R, Moorganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial. Eur Resp J. 2013. doi: 10.1183\/09031936.00104612 .","DOI":"10.1183\/09031936.00104612"},{"key":"156_CR14","unstructured":"Actelion Study Meta Data Registry (SMADAR). A multi-center, double-blind, randomized, placebo-active-controlled, dose-ranging study to evaluate the efficacy and safety of Actelion-1 in subjects with mild-to-moderate essential hypertension. 2013. http:\/\/trials.actelion.com\/asp\/Trial_Registry\/RStudyInfo.asp?ST=AC-055-201 . Accessed 18 Nov."},{"key":"156_CR15","unstructured":"Nippon Shinyaku Co Ltd. Nippon Shinyaku enters into a license agreement with Actelion on a novel PAH development compound [media release]. http:\/\/www.nippon-shinyaku.co.jp\/english\/news\/ns2010\/2154 . Accessed 17 Feb 2010."},{"issue":"3","key":"156_CR16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","volume":"327","author":"M Iglarz","year":"2008","unstructured":"Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327(3):736\u201345.","journal-title":"J Pharmacol Exp Ther"},{"key":"156_CR17","doi-asserted-by":"crossref","unstructured":"Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One. 2012. doi: 10.1371\/journal.pone.0047662 .","DOI":"10.1371\/journal.pone.0047662"},{"issue":"2","key":"156_CR18","first-page":"455","volume":"27","author":"C Corallo","year":"2013","unstructured":"Corallo C, Pecetti G, Iglarz M, et al. Macitentan slows down the dermal fibrotic process in systemic sclerosis: in vitro findings. J Biol Regul Homeost Agents. 2013;27(2):455\u201362.","journal-title":"J Biol Regul Homeost Agents"},{"key":"156_CR19","doi-asserted-by":"crossref","unstructured":"Iglarz M, Landskroner K, Rey M, et al. Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension [abstract no. A6445]. Am J Respir Crit Care Med. 2011;183:D36.","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A6445"},{"key":"156_CR20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.lfs.2012.03.032","volume":"91","author":"S Sen","year":"2012","unstructured":"Sen S, Chen S, Feng B, et al. Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist. Life Sci. 2012;91:658\u201368.","journal-title":"Life Sci"},{"issue":"2","key":"156_CR21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1593\/neo.10806","volume":"13","author":"S-J Kim","year":"2011","unstructured":"Kim S-J, Kim JS, Kim SW, et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia. 2011;13(2):167\u201379.","journal-title":"Neoplasia"},{"issue":"1","key":"156_CR22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1593\/tlo.11286","volume":"5","author":"S-J Kim","year":"2012","unstructured":"Kim S-J, Kim JS, Kim SW, et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol. 2012;5(1):39\u201347.","journal-title":"Transl Oncol"},{"issue":"10","key":"156_CR23","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","volume":"67","author":"PN Sidharta","year":"2011","unstructured":"Sidharta PN, van Giersbergen PLM, Halabi A, et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol. 2011;67(10):977\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"156_CR24","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/jcph.152","volume":"53","author":"PN Sidharta","year":"2013","unstructured":"Sidharta PN, van Giersbergen PLM, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol. 2013;53(11):1131\u20138.","journal-title":"J Clin Pharmacol"},{"key":"156_CR25","first-page":"S108","volume":"93","author":"PN Sidharta","year":"2013","unstructured":"Sidharta PN, Lindegger N, Reseski K, et al. Macitentan, a novel dual endothelin receptor antagonist, does not prolong the QT\/QTC interval in a thorough QTC study in healthy subjects [abstract no. PIII-61]. Clin Pharmacol Ther. 2013;93:S108\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"156_CR26","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/00498254.2012.664665","volume":"42","author":"S Bruderer","year":"2012","unstructured":"Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica. 2012;42(9):901\u201310.","journal-title":"Xenobiotica"},{"issue":"5\u20136","key":"156_CR27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000351704","volume":"91","author":"S Bruderer","year":"2013","unstructured":"Bruderer S, Marjason J, Sidharta PN, et al. Pharmacokinetics of macitentan in caucasian and Japanese subjects: the influence of ethnicity and sex. Pharmacology. 2013;91(5\u20136):331\u20138.","journal-title":"Pharmacology"},{"key":"156_CR28","author":"PN Sidharta","year":"2013","unstructured":"Sidharta PN, Lindegger N, Ulc I, et al. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment. J Clin Pharmacol. 2013;. doi: 10.1002\/jcph.193 .","journal-title":"J Clin Pharmacol"},{"issue":"1\u20133","key":"156_CR29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2013.01.010","volume":"701","author":"J Weiss","year":"2013","unstructured":"Weiss J, Theile D, Ruppell MA, et al. Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro. Eur J Pharmacol. 2013;701(1\u20133):168\u201375.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"156_CR30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","volume":"52","author":"J Atsmon","year":"2013","unstructured":"Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013;52(8):685\u201392.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"156_CR31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/s12248-011-9316-3","volume":"14","author":"S Bruderer","year":"2012","unstructured":"Bruderer S, Aanismaa P, Homery M-C, et al. Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist. AAPS J. 2012;14(1):68\u201378.","journal-title":"AAPS J"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-013-0156-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-013-0156-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T20:23:23Z","timestamp":1716236603000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-013-0156-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,3]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1007\/s40265-013-0156-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,3]]}}}